...
This presentation is the property of its rightful owner.
Sponsored Links
1 / 28

1 – контроль. 2 – опыт в 1 установке. 3 – опыт во 2 установке (магнитный экран ). PowerPoint PPT Presentation


  • 93 Views
  • Uploaded on
  • Presentation posted in: General

Ряд высокоамплитудных эффектов слабых и сверхслабых магнитных полей и их вероятные молекулярные механизмы. Докладчик В.В. Новиков. 1 – контроль. 2 – опыт в 1 установке. 3 – опыт во 2 установке (магнитный экран ).

Download Presentation

1 – контроль. 2 – опыт в 1 установке. 3 – опыт во 2 установке (магнитный экран ).

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


1 2 1 3 2

.

..


1 2 1 3 2

1 .

2 1 .

3 2 ( ).

( 42 ; 0,1 , 3,7 ; 4 ) Dugesia tigrina. (n=50).


1 2 1 3 2

1 1 .

2 2 ( ).

Dugesia tigrina ( 42 ; 0,1 ; 4 ).


1 2 1 3 2

Dugesia tigrina ( 42 ; - 3,7 ; 4 ).


Dugesia tigrina

1 ( 42 ; 0,1 ,

3,7 ; 4 ).

2 (0,1 , 3,7 ; 4 ).

3 ( 4 ).

Dugesia tigrina.


1 2 1 3 2

: , , , ; ( ), ; . .


1 2 1 3 2

1 - 3,5-5,0 ;2 - 4 ;3 - 32,2 ;4 - 50 ;5 - 3,5-5,0 , ;6 - .

- SHK ( 1*106 /) ( 42 ; - 50 )


1 2 1 3 2

1 - 50 ;2 - 500 ;3 - 5000 ;

4 - .

- CBA ( 1*106 /) (- 42 ; - 3,5-5,0 ) .


1 2 1 3 2

1 - 2 1- 14- ;

2 - 30 1- 14- ;

3 - 6 1- 14- ;

4 - 2 5- 14- ;

5 - .

- 57Bl ( 1*106 /) (- 42 ; - 50 , 3,5-5,0 ) .


1 2 1 3 2

(=42 ; =100 ) .


1 2 1 3 2

A=A0sin1t+A0sin2t=2A0sin(1+2)t/2cos(1-2)t/2


1 2 1 3 2

( =80 ; 4,38 4,88 ) .


1 2 1 3 2

(=42 ; 4,38 4,88 ) .


1 2 1 3 2

, . , 10- . - 30


1 2 1 3 2

1 - 2 1- 40- ;

2 -

- Balb ( 2*105 /) ( - 42 ; - 50 , 3,5-5,0 ).


1 2 1 3 2

( ) . , 80- . - 30


1 2 1 3 2

. 80- .- 1


1 2 1 3 2

-

, : (30-49 ) (3,5-5,0 ; 50-120 ) () , ; - , () ; - , ; , ; , ( , ), , , , .


1 2 1 3 2

1 - (10) + I (0,1);

2 - (10) + I (0,1)+ ;

3 - (10) + I (0,1).

4 - (10) + I (0,1);

5 - (10) + I (0,1) + ;

6 - (10) + I (0,1).

() I 4 ( - 40 ; - 40 , 3,5-5,0 ). .


1 2 1 3 2

1 - (10) + I (0,1);

2 - (10);

3 - (10) + I (0,1) + - (10).

1 - (10) + I (0,1);

2 - (10);

3 - (10) + I (0,1) + 3 (10).

I - . .


1 2 1 3 2

1 - (10) + ;

2 - (10) + I (0,1);

3 - (10) + I (0,1) + - 3 (10),

.

4 - (10) + I (0,1) + (10),

.

- I 2 in vitro ( - 40 ; - 40 , 3,5-5,0 ).


1 2 1 3 2

- .

, 3, I. - I ( 3) , . , , , .


1 2 1 3 2

HPLC 3 (30 /) (=42 ; =0,05 , 3,5-5,0 ; 12 ).


1 30 n 5 12

1 (30 /) (n=5). -12

1. .

2. .

3. ( 12 ).

4. (10 /).

5. ABTS ( 10 /).

6. (10 /).

7. (pepstatin - 1 /; aprotinin - 2 /; leupeptin 1 - /; chymostatin - 3 /).


1 2 1 3 2

1. -1 (4.5% ..) 2. - (7.4 % .)3.- (2.9 % ..)4.- (6.7 % ..)5. (2.0 % ..)6. (3.7 % ..)7. (6.0 % ..)8. (2.5 % ..)

(30 /) (=42 ; =0,05 , 3,5-5,0 ; 12 ) (n=5).


1 2 1 3 2

1 (=42 ; =0,05 , 3,5-5,0 ; 12 ) (n=5).


1 2 1 3 2

1

1 (Asp)DRV(Val) 2 (Fhe)FHL(Leu) 3 (Asp)DRVYI(Ile)

4 (His)HPFHL(Leu)

-

1 (Gln)QCCASVCSV(Val) 2 (Asn)NYCN(Asn)

3 (Gly)GIVEQCCASVCSL(Leu) 4 (Tyr)YQLE(Glu)

-

1 (Tyr)YTPKA(Ala) 2 (Tyr)YLVCGERGFF(Fhe)

3 (Tyr)YLVCGERGFFYTPKA(Ala)

4 (Fhe)FVNQHLVGSHLVGAL(Leu)

-

1 DAEFRHD (Asp)

2 (Ser)SGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV


1 2 1 3 2

.

, , . , , : , , ; , ; . . , , , , . .


  • Login